Crinetics Pharmaceuticals is a pharmaceutical company focusing on the development of novel therapeutics, targeting peptide hormone receptors, and treatment of endocrine-related diseases and cancers. Founded in 2008 in San Diego, CA, this small yet dedicated team of 50 employees operates with an annual revenue of $71,000. With all programs derived from internal discovery efforts, Crinetics aims to reduce both the risk and cost in achieving meaningful clinical data by using objective hormonal biomarker endpoints for preclinical and clinical studies.
Under the leadership of CEO Scott R. Struthers, Crinetics Pharmaceuticals pursues its mission to build the leading endocrine company that consistently pioneers new therapeutics to help patients better control their diseases and improve their daily lives. The organization actively seeks motivated partners to advance their programs and transform them into commercially successful products, ultimately bringing their vision to life.
